Biocon Biologics Ltd (BBL), a subsidiary of Biocon Ltd, has finalized a distribution agreement with Sandoz. The deal grants exclusive rights for the promotion, sale, and distribution of “Adalimumab BS for subcutaneous injection [FKB]” in the Japanese market, effective immediately.
“Adalimumab BS for subcutaneous injection [FKB]” is a biosimilar of Humira, providing therapeutic solutions for immune system related diseases like rheumatoid arthritis, psoriasis vulgaris, ankylosing spondylitis, Crohn’s disease, and ulcerative colitis. Its launch in Japan is expected to meet the medical needs of patients struggling with these conditions.
The Adalimumab Biosimilar Market, valued at $613.28 million in 2022, is projected to reach $3954.75 million by 2031, reflecting a significant 23.2% Compound Annual Growth Rate (CAGR) during the forecast period.
This development follows Biocon Biologics’ acquisition of Viatris’ global biosimilar portfolio, including the coveted Adalimumab. The developer of the drug, Fujifilm Kyowa Kirin Biologics Co Ltd, has entered into an exclusive global marketing license agreement with Biocon Biologics Ltd affiliate.
Under the agreement, Viatris concluded the marketing and promotion of the biosimilar product on December 15, 2023. Transition support from Viatris will continue until February 15, 2024, after which Sandoz will gradually assume full responsibility for the distribution of Adalimumab BS.
Biocon Biologics recently achieved a milestone by successfully integrating Viatris’ biosimilars business in 120 countries ahead of schedule. Globally, Biocon Biologics boasts a robust pipeline of 20 assets spanning diabetology, oncology, immunology, and ophthalmology.
